New drug cocktail hopes to tackle tough lung cancer

NCT ID NCT07232849

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a new drug called HRS-4508, given as a tablet, together with other anticancer drugs (SHR-A1811 and/or Adebrelimab) in 100 adults with advanced non-small cell lung cancer that has not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the combination shrinks tumors. Researchers will also monitor how long any benefit lasts and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4508 tablet combined with other anticancer drugs (SHR-A1811 and/or Adebrelimab)
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer who have not responded to standard therapies.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The combination drugs may cause side effects, and it is not yet known if they will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200430, China
Zhejiang Tumor Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.